
    
      This study is a post-marketing, open-label, prospective and multicentric pilot study in 50
      patients suffering from knee OA. Investigators will be rheumatologists or articular disease
      specialists from public or academic hospitals located in Belgium and France. In each
      investigating center, the same injector will perform all the VS.
    
  